Last updated on April 23, 2014 at 20:10 EDT

Latest Multiple Myeloma Research Consortium Stories

2006-01-09 07:44:20

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma. The drug, also known as thalidomide, was first introduced in the 1950s and became notorious for causing birth defects. It is currently approved for treating a symptom of leprosy. The Phase 3 trial of 270 patients found that that it took an average of 75.7 weeks for...